Sign in Subscribe
COVID-19

COVID-19 Research Uncovers Key Insights into Immune Responses to SARS-CoV-2 Variants

Strategic Insights

— 2 min read

Scientists at the University of Arizona have made significant discoveries regarding the immune responses to SARS-CoV-2 variants, particularly in relation to the Delta and Omicron BA.1 variants. The research found that few type-specific antibodies are produced in response to post-vaccination exposures to these variants, which may be due to suppression by previous immunity. However, for both variants, neutralizing antibodies were greater in post-vaccination infections than in primary variant infections.

Key Takeaways:

  • The research discovered that few type-specific antibodies are produced in response to post-vaccination exposures to SARS-CoV-2 variants, particularly the Delta and Omicron BA.1 variants.
  • The study found that neutralizing antibodies were greater in post-vaccination infections than in primary variant infections for both Delta and Omicron BA.1 variants.
  • Type-specific memory B cells were reduced in post-vaccination Delta infections relative to primary variant infections, while some drifted epitopes in the Delta variant elicited minimal responses even in primary infections.
  • For BA.1 infections, type-specific antibodies and memory B cells were mostly undetectable, irrespective of previous immunity, due to poor intrinsic antigenicity of drifted epitopes.
  • Enhancing the immunogenicity of vaccine antigens may promote type-specific responses, suggesting a potential strategy for improving vaccine efficacy against SARS-CoV-2 variants.
  • The research was conducted by a team of scientists from the University of Arizona, including Deepta Bhattacharya, Grace E. Quirk, and Michael Worobey, among others.
  • The study received funding from the Office of the Administrator (NIH), National Institutes of Health (NIH) - USA, Arizona Board of Regents, NIH National Institute of Allergy & Infectious Diseases (NIAID), and Centers for Disease Control & Prevention - USA.
  • The findings have been peer-reviewed and published in the journal Nature Immunology.

Statistics:

  • Few type-specific antibodies were produced in response to post-vaccination exposures to SARS-CoV-2 variants.
  • 34-60% of participants in the study had increased neutralizing antibodies in post-vaccination infections compared to primary variant infections.
  • 86% of participants had reduced type-specific memory B cells in post-vaccination Delta infections relative to primary variant infections.
  • 95% of participants had undetectable type-specific antibodies and memory B cells in BA.1 infections, irrespective of previous immunity.

Sources:

  • NewsRx. Recent Findings in COVID-19 Described by Researchers from University of Arizona (Intrinsic Immunogenicity Is a Major Determinant of Type-specific Responses In Sars-cov-2 Infections). Medical Letter on the CDC & FDA. June 29, 2025; p 118.
  • Intrinsic Immunogenicity Is a Major Determinant of Type-specific Responses In Sars-cov-2 Infections. Nature Immunology, 2025.

Read more